Cold chain mastery as a market differentiator
The only viable route involved a cargo aircraft and a connection in Luxembourg, where a delay or missed departure could leave the shipment waiting for an uncertain length of time, increasing the risk of product loss and delays to patient treatment.
The pallet-sized shipping system used blocks of dry ice and had been tested to maintain the required temperature for five days. But it couldn’t be easily replenished en route, and transferring the product to another container would create further risk.
The team needed to know whether the thermal protection would last through the journey and any disruption, including a missed connection or a delay after arrival in Brazil, and how much time they’d have to respond.
Before departure, thermal modeling allowed the team to test how the packaging would perform if the journey changed. Richard Peck, Director of Global Packaging Solutions at World Courier, recalls that real-time temperature data could also be fed into the model if disruption occurred, giving the team an updated picture of how long the protection would last.
The shipment reached Brazil safely, without the contingency measures being called upon. That was the payoff: the risks had already been tested, the options understood, and the team was ready to act if the journey went off course.
That real-life example captures a wider lesson for procurement: a journey plan is only as strong as the thinking behind it. Buyers need to understand where its limits lie, how changing conditions will be monitored, and which options remain if disruption strikes.
Richard sees cold-chain mastery as choosing the right solution for the product and route.
Richard Peck
Director, Global Packaging Solutions, World Courier
Test the thinking behind the proposed service before comparing prices. Does the provider understand the product and the complete journey? Has it explored what could go wrong? Can it explain what the customer will see, who’ll respond, and which options will be available?
These answers reveal whether the provider is offering a box and a route, or a cold-chain strategy.
Define the requirement before comparing solutions
A broad packaging portfolio is only useful if the provider can identify the right option and explain why it fits the product, payload, route, and risk profile.
Procurement should give every potential partner the same operating brief, covering:
- The product temperature range and known stability information
- The payload size, value, and consequences if it must be replaced
- The origin, destination, expected journey time, and handover points
- The visibility and intervention required during transit
- The level of acceptable risk and the contingency time the packaging must provide
- The cost and sustainability objectives that must be achieved without compromising product protection
When every potential provider prices against the same operating brief, procurement can compare proposals more fairly. A lower quote may exclude monitoring, recovery support, assessed alternatives, or extended thermal protection to manage disruption. At the other extreme, procurement may pay for an overengineered solution designed for conditions the shipment is unlikely to encounter.
Richard has watched this approach evolve during 20 years working on both the customer and supplier sides of pharmaceutical logistics. Earlier in his career, providers often promoted the packaging assets they already had. Broader portfolios and better analytical tools now allow them to match different products and routes with more appropriate solutions.
Ask providers which options they rejected, why they rejected them, and how the recommended solution was selected. Their answers will show whether the proposal reflects a genuine assessment or the inventory they happen to have available.
Test the plan before the product moves
A packaging system may perform well under controlled laboratory conditions. A live journey introduces missed connections, changing ambient temperatures, customs delays, different payloads, and longer-than-expected transit times. Thermal modeling allows teams to explore those variables before the product moves.
Richard co-led an International Safe Transit Association (ISTA) Pharma Committee white paper on thermal modeling and simulation. It explains how simulation can assess different payloads, temperature profiles, journey times, and packaging configurations. Teams can also use it to evaluate route changes and compare the cost and sustainability implications of alternative shipping systems.2
Physical testing remains the foundation. Modeling builds on that evidence by allowing teams to examine more scenarios and uncover risks that a single laboratory test may not reveal.
The China-to-Brazil shipment shows the difference. Modeling turned a five-day laboratory result into a route-specific assessment, helping the team estimate how long the protection would last and how conditions after arrival could affect the time available. If the journey had been disrupted, live ambient temperature data could have refined that assessment and informed the response.
Procurement teams can test this rigor without specifying the modeling technology. Ask which assumptions support the recommendation, which disruptions have been examined, and what evidence shows that the packaging and route work together. Before awarding or implementing a critical service, review scenarios such as missed connections, customs delays, route changes, and extended exposure at the destination.
Connect visibility to an agreed response
A temperature alert doesn’t protect a shipment. The response it triggers can.
Live location and temperature monitoring may provide an earlier warning, but procurement teams must establish who watches the data, what triggers an alert, who has authority to intervene, and what the provider can do at each stage of the route.
This operational clarity supports the European Union’s good distribution practice guidelines, which require medicinal products to be protected during transportation and specified conditions to be maintained. Deviations must be documented, investigated, and addressed through corrective and preventive action.3
Richard Peck
Choose the monitoring around the risk. The highest specification won’t be necessary for every movement. Decide where real-time visibility could change the outcome and where retrospective data will meet the quality requirement at a lower cost.
Thermal modeling can make live data more useful. The ISTA paper explains that combining simulation with near-real-time monitoring, forecast conditions, or historical ambient data could predict an excursion early enough for corrective action.2
AI may eventually accelerate those predictions and support decisions such as where to position reusable packaging fleets. Richard identifies data quality as the condition: “If the data’s good, AI can predict when things are happening and provide the notifications,” he says.
Ask providers how they validate source data, explain their recommendations, and maintain human accountability for decisions involving product quality and patient risk. Technology should give teams more time and better options while keeping responsibility clear.
Assess sustainability across the complete journey
A solution can look sustainable at the point of purchase, but lose that advantage across the complete journey.
A lighter package may reduce freight emissions. A reusable system may reduce waste. Road or ocean transport may lower emissions on an appropriate route. Those benefits can be offset by additional handling, return movements, longer lead times, or greater product risk. Cost and sustainability may point in the same direction, but they won’t always do so.
Generic UK Government conversion factors illustrate the scale of the difference between transport modes: air freight has a substantially higher emissions factor per tonne-kilometer than road freight or container shipping.4
Those figures can inform the discussion, but they can’t decide a pharmaceutical movement. Compare the complete route, packaging weight, journey time, handling points, product stability, return logistics, and consequences of failure.
Reuse requires the same whole-journey view. A 2026 ISTA Pharma Committee paper to which Richard contributed examines the sustainable management of temperature-monitoring devices. It finds that multi-use devices are particularly well suited to closed-loop distribution, where their return can be controlled. On open international routes, regional refurbishment or recycling may be more practical than sending devices back to their point of origin.5
A poorly designed return network can erase the cost and carbon benefits of reuse. The paper recommends defining responsibility for return costs within quality agreements or service-level agreements and considering regional collection points. Device reliability, recalibration, data security, customs requirements, and the remaining value of the equipment also shape the decision.5
Require the lifecycle case behind any “reusable” or “recyclable” claim. Ask:
- Where will the packaging or monitoring device go after delivery?
- Who owns collection, return, refurbishment, and recycling?
- How many successful cycles does the calculation assume?
- Which mileage, loss rate, and regional infrastructure sit behind the claim?
- How will the provider maintain performance and compliance throughout reuse?
The EU Packaging and Packaging Waste Regulation (PPWR) adds urgency, although its obligations, application dates, and exemptions vary according to the packaging, its use, and the organization’s role.6 Map which packaging enters the EU market, confirm the relevant requirements with appropriate specialists, and include future compliance in sourcing and design reviews.
Use common standards to focus supplier conversations
Common standards help buyers compare like with like. They can’t determine the right solution for every product and route.
Richard’s work with the ISTA Pharma Committee shows how voluntary industry collaboration can provide a shared technical starting point.
Manufacturers, pharmaceutical companies, packaging specialists, logistics providers, and other experts contribute knowledge that individual organizations would otherwise have to develop or assess independently.
Common testing profiles make supplier comparisons more consistent, while leaving room for route-specific judgment. ISTA 7D, for example, can provide a demanding reference for thermal performance.
Applying that profile to a short, controlled last-mile movement could lead to unnecessary packaging, materials, and cost.
Use standards to establish the technical baseline, then focus supplier conversations on where capability genuinely differs. How does the provider apply the guidance? How well does it understand the route? How clearly does it communicate risk? What happens when conditions depart from the plan?
Apply the same discipline to performance data. On-time and in-full delivery remains important, but an excursion count can mislead if it treats an alert within an allowable limit in the same way as an event that causes product loss. Review right-first-time delivery, product loss or damage, investigation quality, response times, and carbon data together.
Select for total value and future capability
A provider chosen for today’s route must also be ready for tomorrow’s disruption.
Capacity conditions can change quickly. The International Air Transport Association reported that global air cargo demand fell 4.8% year over year in March 2026, while available capacity declined by 4.7% overall and 6.8% for international operations.7 The figures don’t describe every route, but they demonstrate why buyers should examine established carrier relationships and assessed alternatives rather than assume capacity will always be available.
Deloitte’s 2025 Global Chief Procurement Officer Survey reinforces those priorities. Among procurement leaders, 74% identified alternative supply sources as one of their most effective risk-mitigation strategies, 64% cited supply chain visibility, and 61% highlighted supplier information sharing and collaboration.8 The survey spans multiple sectors, but its findings align closely with temperature-controlled logistics.
Qualify capability before opening the price comparison. Test:
- Relevant performance: What are the provider’s right-first-time and on-time results for comparable products, routes, and service levels?
- Regional capability: Where does the provider operate directly, and how does it maintain standards across agents, carriers, and subcontractors?
- Packaging and route evidence: Which qualification, modeling, and operating assumptions support the proposed solution?
- Visibility and intervention: What can the customer see, who responds to an alert, and which recovery actions are available?
- Continuity: Which alternative routes, capacity arrangements, and escalation processes have been prepared?
- Lifecycle performance: How will cost, emissions, packaging, and monitoring devices be measured and improved throughout the contract?
Buyers can then compare prices on a like-for-like basis. A higher freight or packaging cost may reduce investigation time, replacement movements, product write-offs, and delays to patients.
The evidence may also show that a less complex solution can provide the required protection at a lower cost and with a smaller environmental footprint.
World Courier brings specialist logistics knowledge, packaging expertise, global operating capability, and visibility into the same assessment. Early engagement gives procurement and quality teams time to compare options while the packaging, route, monitoring, and contingency arrangements can still be changed.
Richard recommends choosing a partner with the capability to grow alongside the organization, rather than treating every movement as an isolated transaction.
“Price is key, but procurement leaders are also looking at value. Am I getting the most value from my partners, and is what I’m paying worth every penny?” he says.
Cold-chain mastery comes down to a disciplined procurement process. Define the requirement. Ask providers to explain their assumptions and contingency plans. Compare viable options across protection, cost, and environmental impact. Then choose the partner that can protect the product when the plan holds and when the journey changes.
References
-
Lawanprasert, A. et al. (2024). “Heat stable and intrinsically sterile liquid protein formulations.” Nature Communications, 15, 10897. https://www.nature.com/articles/s41467-024-55304-9
-
International Safe Transit Association (ISTA) Pharma Committee (2024). Thermal Modeling/Simulation, ISTA PCW-03 Revision 00. Released March 2024. Richard Peck and Ben Vanderplas, co-leads. https://ista.org/ista_pharma_committee_document.php
-
European Commission (2013). Guidelines on Good Distribution Practice of Medicinal Products for Human Use (2013/C 343/01). https://health.ec.europa.eu/document/download/9f28179a-a6f8-418a-a5fc-ecfbb3ae3ba8_en
-
UK Department for Energy Security and Net Zero (2026). Greenhouse gas reporting conversion factors 2026. Published June 11, 2026; updated July 31, 2026. https://www.gov.uk/government/publications/greenhouse-gas-reporting-conversion-factors-2026
-
International Safe Transit Association (ISTA) Pharma Committee (2026). Sustainable Management of Temperature Monitoring Devices, ISTA PCW-08 Revision 00. Released July 2026. https://ista.org/ista_pharma_committee_document.php
-
European Parliament and Council of the European Union (2025). Regulation (EU) 2025/40 on packaging and packaging waste. https://eur-lex.europa.eu/eli/reg/2025/40/oj/eng
-
International Air Transport Association (2026). “Middle East disruption impacts cargo markets, demand falls 4.8% in March.” Published April 29, 2026. https://www.iata.org/en/pressroom/2026-releases/2026-04-29-03/
-
Deloitte (2025). 2025 Global Chief Procurement Officer Survey. https://www.deloitte.com/be/en/services/consulting/research/global-chief-procurement-officer-survey.html